4. Rh Blood Group System

Overview and Clinical Significance of the Rh Blood Group System

• Rank and Primary Importance:

  • The Rh blood group system is the second most clinically significant system in transfusion medicine, preceded only by the ABO system.

  • ABO incompatibility represents the most rapid mechanism of acute hemolytic transfusion fatality, establishing its primary rank; Rh incompatibility is clinically significant due to the nature and persistence of its immune responses.

• Immunoglobulin Class and Clinical Behavior:

  • Antibodies within the Rh blood group system are of the immunoglobulin G ($\text{IgG}$) class.

  • Because $\text{IgG}$ antibodies actively cross the placenta and react optimally at body temperature ($37^\circ\text{C}$), they are capable of mediating severe extravascular red cell destruction, hemolytic transfusion reactions, and Hemolytic Disease of the Fetus and Newborn (HDFN).

• The Five Principal Antigens:

  • The system comprises over $50$ distinct antigens, but clinical focus rests predominantly on five principal antigens: $D$, $C$, $c$, $E$, and $e$.

  • Other clinically notable antigens within the system include $C^w$.

• Status of the Lowercase $d$ Antigen:

  • There is no lowercase $d$ antigen; an antigen corresponding to $d$ has never been discovered or isolated.

  • Lowercase $d$ is utilized solely in notation as an operational placeholder to represent the absence of the $D$ antigen.

  • Despite the absence of a physical $d$ antigen, approximately $15\%$ of the human population is phenotypically Rh-negative, lacking expression of the $D$ polypeptide.

• Written Notation Conventions:

  • To avoid typographical confusion in written records between uppercase $C$ and lowercase $c$, a horizontal line must be placed directly over the lowercase letter (rendered as $\bar{c}$).

  • Failure to distinguish $\bar{c}$ with an overbar risks misidentification as an uppercase $C$, which is graded as incorrect on clinical evaluations.

• Antigen-Antibody Reactivity and Rh Typing:

  • Determination of Rh positivity or Rh negativity depends entirely on agglutination testing using anti-D antiserum.

  • Hemagglutination indicates the presence of the $D$ antigen (Rh-positive status).

  • Lack of agglutination indicates the absence of the $D$ antigen (presumptive Rh-negative status, pending further weak D confirmation where indicated).

• Mechanism of Antibody Formation (Alloimmunization):

  • Unlike ABO antibodies, Rh antibodies are not naturally occurring. An individual must undergo immune stimulation via foreign red cell exposure to produce them.

  • Exposure occurs exclusively through two pathways:

  • Pregnancy with an Rh-incompatible fetus.

  • Allogeneic blood transfusion containing foreign Rh antigens.

  • Exposure of an Rh-negative individual to Rh-positive red cells carries a high rate of immunogenicity: $50\%$ to $70\%$ (or greater) of Rh-negative recipients will form immune anti-D antibodies.

History, Discovery, and Comparative Antigens

• Landsteiner and Wiener Animal Experiments:

  • Karl Landsteiner and Alexander S. Wiener discovered the system by immunizing rabbits and guinea pigs with red blood cells from rhesus monkeys (Macaca mulatta).

  • The resulting animal antibodies caused hemagglutination when mixed with human red blood cells, leading to the designation of the "Rh" antibody.

• Distinction Between LW and Anti-Rh:

  • Further characterization revealed that the antibody produced by animals and the antibody produced by humans are not immunologically identical, although they demonstrate parallel agglutination patterns.

  • The animal-derived antibody is designated as anti-LW (named in honor of Landsteiner and Wiener).

  • The human-derived alloantibody is designated as anti-Rh (anti-D).

  • Anti-LW reacts strongly with Rh-positive adult red cells, weakly with Rh-negative adult red cells, and strongly with cord blood cells regardless of Rh type, distinguishing it from true anti-D.

  • Mastery of the distinction between Landsteiner-Wiener (LW) and Rh systems is a mandatory standard for medical laboratory certification examinations (such as CSMLS and Caliber).

Theories of Rh System Genetic Inheritance

• Tippett Molecular Genetic Model (1993):

  • Represents the accepted modern genetic standard for the Rh system.

  • Demonstrates that Rh antigens are encoded by two distinct, highly homologous, closely linked structural genes located on the short arm of chromosome 1:

  • $RHD$: Directs the synthesis of the RhD membrane protein, which carries the $D$ antigen.

  • $RHCE$: Directs the synthesis of the RhCE membrane protein, which encodes the $C$, $c$, $E$, and $e$ antigens through alternative splicing and specific amino acid substitutions (yielding combinations $Ce$, $cE$, $ce$, or $CE$).

  • Rh-negative individuals typically possess a complete deletion of the $RHD$ gene (in populations of European ancestry) or harbor an inactive/mutated $RHD$ gene sequence.

• Fisher-Race Genetic Theory (1940s–1990s):

  • Postulates that the Rh locus comprises three separate, closely linked gene pairs that do not undergo independent assortment but are inherited together as a haplotype.

  • The three discrete loci correspond to $D/d$, $C/c$, and $E/e$.

  • Each allele directs the production of a single, distinct antigen on the red cell surface (with lowercase $d$ functioning as an unexpressed or silent allele).

  • C-locus alleles ($C$ and $c$) and E-locus alleles ($E$ and $e$) are codominant.

  • Eight potential combinations/haplotypes are generated: $DCe$, $DcE$, $Dce$, $DCE$, $dce$, $dCe$, $dcE$, and $dCE$.

  • Conventional notation orders can place $C$ first ($CDE$) or $D$ first ($DCE$); ordering $D$ first facilitates immediate identification of Rh-positive versus Rh-negative clinical status.

• Wiener Theory:

  • Postulates that inheritance is governed by a single genetic locus containing multiple allelic genes.

  • A single gene at this locus directs the expression of an entire complex agglutinogen on the erythrocyte membrane.

  • Each agglutinogen is composed of multiple individual antigenic specificities termed "factors" (for example, the $Rh_1$ agglutinogen contains factors $Rh_0$, $rh'$, and $hr''$, corresponding to $D$, $C$, and $e$).

  • Wiener identified eight primary alleles at this single locus: $R^0$, $R^1$, $R^2$, $R^z$, $r$, $r'$, $r''$, and $r^y$.

Antigen Characteristics, Population Frequencies, and Dosage

• Antigen Frequencies Across the General Population:

  • $D$: Expressed in approximately $85\%$ of individuals (Rh-positive); $15\%$ lack the antigen (Rh-negative).

  • $C$: Present in approximately $70\%$ of the population.

  • $E$: Present in approximately $30\%$ of the population.

  • $c$: Present in approximately $80\%$ of the population.

  • $e$: Present in approximately $98\%$ of the population.

  • Because $e$ expression is nearly universal ($98\%$), finding compatible donor units for an individual who develops an anti-e alloantibody is clinically difficult, whereas anti-e antibody formation is comparatively infrequent across the general population.

• Allelic Relationships:

  • $C$ and $c$ function as true antithetical alleles.

  • $C^w$ represents an alternative allele at the $C/c$ locus.

  • $E$ and $e$ function as true antithetical alleles.

• Dosage Effect in the Rh System:

  • Dosage occurs when an antibody reacts more vigorously with red blood cells expressing homozygous antigen density than with cells expressing heterozygous antigen density.

  • Antigens belonging to the $C/c$ and $E/e$ allelic pairs clearly display dosage:

  • Red cells with genotype $CC$ demonstrate stronger serologic agglutination with anti-C than cells with genotype $Cc$.

  • Red cells with genotype $ee$ demonstrate stronger serologic agglutination with anti-e than cells with genotype $Ee$.

  • The $D$ antigen does not demonstrate serologic dosage:

  • Because no lowercase $d$ antigen or anti-d antibody exists, distinguishing between homozygous ($DD$) and heterozygous ($Dd$) phenotypes cannot be accomplished via direct serological antisera agglutination testing, requiring genomic/molecular DNA analysis instead.

  • Consequently, $D$ is clinically classified as failing to demonstrate dosage in routine pre-transfusion serology.

Nomenclature Systems: Wiener, Fisher-Race, Rosenfield, and ISBT

• Rules for Wiener and Fisher-Race Equivalence:

  • A capital letter $R$ in Wiener signifies the presence of the $D$ antigen (Rh-positive).

  • A lowercase letter $r$ in Wiener signifies the absence of the $D$ antigen (Rh-negative, represented by $d$).

  • The number $0$ (zero) or the absence of an accent mark on lowercase $r$ indicates that both other factors are lowercase ($c$ and $e$).

  • The number $1$ or a single prime ($'$) indicates the presence of uppercase $C$.

  • The number $2$ or a double prime ($''$) indicates the presence of uppercase $E$.

  • The letter $z$ (paired with capital $R$) or the letter $y$ (paired with lowercase $r$) signifies that both uppercase $C$ and uppercase $E$ are present simultaneously.

• Translation Table for the Eight Standard Haplotypes:

  • $R^0$ corresponds to Fisher-Race $Dce$.

  • $R^1$ corresponds to Fisher-Race $DCe$.

  • $R^2$ corresponds to Fisher-Race $DcE$.

  • $R^z$ corresponds to Fisher-Race $DCE$ (an exceptionally rare haplotype).

  • $r$ corresponds to Fisher-Race $dce$ (the most frequent Rh-negative haplotype; homozygous $rr$ is $dce/dce$).

  • $r'$ corresponds to Fisher-Race $dCe$.

  • $r''$ corresponds to Fisher-Race $dcE$.

  • $r^y$ corresponds to Fisher-Race $dCE$ (an exceptionally rare Rh-negative haplotype).

• Syntax and Symbolism Standards:

  • In Wiener nomenclature, superscripts designate genes (e.g., $R^1$, $r'$), whereas subscripts designate agglutinogens or phenotypic antigens (e.g., $Rh_1$, $rh'$).

  • Lowercase $r$ can never be combined with numerical values 1 or 2; writing "$r^1$" or "$r^2$" is incorrect. Lowercase $r$ designations must strictly use prime ($'$) and double prime ($''$).

• Rosenfield Numeric Nomenclature (1962):

  • Developed to provide an unambiguous, non-theoretical classification suitable for computerized laboratory information systems and digital data entry.

  • Antigens are assigned specific numerical designations:

  • $Rh1 = D$

  • $Rh2 = C$

  • $Rh3 = E$

  • $Rh4 = c$

  • $Rh5 = e$

  • Syntax Rules:

  • Must always begin with the prefix "$Rh:$" followed immediately by numbers separated by commas or spaces.

  • An expressed antigen is written as a simple positive integer.

  • An unexpressed/negative antigen is written with an explicit minus sign ($-$) preceding the integer.

  • Unchecked or untested antigens are excluded from the sequence.

  • Example: A red blood cell reacting positively with anti-D, anti-C, anti-c, and anti-e antisera, but negatively with anti-E antiserum, is entered into Rosenfield nomenclature as $Rh:1, 2, -3, 4, 5$.

• ISBT (International Society of Blood Transfusion) System:

  • An international numeric standard allocating a distinct six-digit identifier to every validated blood group antigen.

  • The first three digits identify the blood group system; the Rh blood group system is assigned system code $004$.

  • The terminal three digits specify the specific antigen (e.g., $004001$ corresponds to $D$, $004002$ corresponds to $C$, $004003$ corresponds to $E$, $004004$ corresponds to $c$, and $004005$ corresponds to $e$).

Genotype and Phenotype Determination and Antibody Prediction

• Distinction Between Phenotype and Genotype:

  • Phenotype represents the direct serological reactivity observed when red cells are exposed to specific commercial antisera ($\text{anti-D}$, $\text{anti-C}$, $\text{anti-E}$, $\text{anti-c}$, $\text{anti-e}$.

  • Genotype represents the actual paired allelic makeup inherited from both parents; it can only be definitively proven via multi-generational family pedigree studies or molecular DNA testing.

  • In routine clinical laboratory practice, probable genotypes are inferred from observed phenotypes based on known population frequency tables.

• Step-by-Step Logic for Deducing Probable Genotypes:

  • Step 1: Evaluate the D Antigen:

  • If anti-D is negative, the genotype is unequivocally homozygous for the absence of D; write $d$ on both chromosomal homologues ($d/d$).

  • If anti-D is positive, the individual possesses at least one $D$ allele; write $D$ on the first chromosome. Because true homozygosity versus heterozygosity cannot be determined by serology, either $D/D$ or $D/d$ can be designated, with $D/d$ conventionally utilized as the standard conservative assumption.

  • Step 2: Evaluate the C and c Antigens:

  • If positive for $C$ and negative for $c$, place $C$ on both chromosomal homologues ($C/C$).

  • If negative for $C$ and positive for $c$, place $c$ on both chromosomal homologues ($c/c$).

  • If positive for both $C$ and $c$, assign one $C$ to one homologue and one $c$ to the other homologue.

  • Step 3: Evaluate the E and e Antigens:

  • If positive for $E$ and negative for $e$, place $E$ on both chromosomal homologues ($E/E$).

  • If negative for $E$ and positive for $e$, place $e$ on both chromosomal homologues ($e/e$).

  • If positive for both $E$ and $e$, assign one $E$ to one homologue and one $e$ to the other homologue.

  • Step 4: Resolve Haplotype Linkage:

  • Align the assigned alleles into standard recognized haplotypes, prioritizing the most prevalent population frequencies (e.g., preferentially linking $D$ with $C$ and $e$ as $DCe$, or $D$ with $c$ and $E$ as $DcE$, while avoiding the extremely rare $DCE$ / $R^z$ combination unless serologically forced).

• Predicting Alloantibody Formation Potential:

  • An individual lacks immune tolerance to any antigen absent from their own erythrocyte membrane.

  • If transfused with antigen-positive red cells or challenged during pregnancy, the recipient can form alloantibodies targeted specifically against those missing antigens.

• Detailed Case Worksheets:

  • Case 1:

  • Serology: Anti-D (+), Anti-C (+), Anti-c (-), Anti-E (-), Anti-e (+).

  • Antigen profile: Possesses $D$, $C$, $e$; lacks $c$, $E$.

  • Fisher-Race genotype: $DCe/DCe$ (or $DCe/dCe$).

  • Wiener genotype: $R^1R^1$ (or $R^1r'$).

  • Potential alloantibodies: Anti-c, anti-E.

  • Case 2:

  • Serology: Anti-D (-), Anti-C (-), Anti-c (+), Anti-E (+), Anti-e (+).

  • Antigen profile: Possesses $c$, $E$, $e$; lacks $D$, $C$.

  • Fisher-Race genotype: $dcE/dce$.

  • Wiener genotype: $r''r$.

  • Potential alloantibodies: Anti-D, anti-C.

  • Case 3:

  • Serology: Anti-D (-), Anti-C (+), Anti-c (-), Anti-E (-), Anti-e (+).

  • Antigen profile: Possesses $C$, $e$; lacks $D$, $c$, $E$.

  • Fisher-Race genotype: $dCe/dCe$.

  • Wiener genotype: $r'r'$.

  • Potential alloantibodies: Anti-D, anti-c, anti-E.

  • Case 4:

  • Serology: Anti-D (+), Anti-C (-), Anti-c (+), Anti-E (+), Anti-e (+).

  • Antigen profile: Possesses $D$, $c$, $E$, $e$; lacks $C$.

  • Fisher-Race genotype: $DcE/dce$ (or $DcE/DcE$, $DcE/dcE$).

  • Wiener genotype: $R^2r$ (or $R^2R^2$, $R^2r''$).

  • Potential alloantibodies: Anti-C.

  • Case 5:

  • Serology: Anti-D (+), Anti-C (+), Anti-c (-), Anti-E (+), Anti-e (+).

  • Antigen profile: Possesses $D$, $C$, $E$, $e$; lacks $c$.

  • Fisher-Race genotype: $DCE/DCe$ (or $DCE/dCe$).

  • Wiener genotype: $R^zR^1$ (or $R^zr'$).

  • Potential alloantibodies: Anti-c.

  • Case 6:

  • Serology: Anti-D (+), Anti-C (-), Anti-c (+), Anti-E (-), Anti-e (+).

  • Antigen profile: Possesses $D$, $c$, $e$; lacks $C$, $E$.

  • Fisher-Race genotype: $Dce/Dce$ (or $Dce/dce$).

  • Wiener genotype: $R^0R^0$ (or $R^0r$).

  • Potential alloantibodies: Anti-C, anti-E.

• Punnett Square Inheritance Scenario:

  • Mating: An Rh-negative parent ($dd$) and an Rh-positive heterozygous parent ($Dd$).

  • Gamete production:

  • Rh-negative parent contributes: $d$ ($100\%$).

  • Rh-positive parent contributes: $D$ ($50\%$) or $d$ ($50\%$).

  • Offspring statistical breakdown:

  • $50\%$ heterozygous Rh-positive ($Dd$) expressing the dominant $D$ antigen.

  • $50\%$ homozygous Rh-negative ($dd$) expressing no $D$ antigen.

Clinical Management: Intrauterine Transfusions and Alloimmunization

• Pathophysiology of Hemolytic Disease of the Fetus and Newborn (HDFN):

  • Maternal primary immunization occurs during a prior pregnancy with an Rh-positive fetus or through mismatched transfusion.

  • Subsequent pregnancy with an Rh-positive fetus triggers secondary anamnestic production of maternal anti-D $\text{IgG}$.

  • Maternal $\text{IgG}$ anti-D crosses the placental syncytiotrophoblast into the fetal circulation.

  • The antibody binds to fetal Rh-positive erythrocytes, leading to their premature destruction by fetal splenic macrophages.

  • Consequences include profound fetal anemia, hepatosplenomegaly, high-output cardiac failure, hydrops fetalis, and potential death in utero.

• Specifications of Blood Units for Intrauterine Transfusion (IUT):

  • ABO/Rh Type: Group O, Rh-negative ($O^-$) red blood cells, ensuring compatibility with both maternal antibody and fetal serum.

  • Unit Age: Extremely fresh unit; less than 7 days old to ensure maximum erythrocyte survival, physiological levels of 2,3-diphosphoglycerate ($\text{2,3-DPG}$, and minimal extracellular potassium accumulation.

  • Hemoglobin S Screening: Must test negative for Hemoglobin S (sickle cell trait negative) to avoid erythrocyte sickling in the low oxygen tension environment of the fetal circulation.

  • Additional Safety Requirements: Must be irradiated (to prevent Transfusion-Associated Graft-versus-Host Disease), Cytomegalovirus (CMV) negative or leukocyte-reduced, and crossmatch-compatible with maternal serum.

• Mechanism and Execution of Procedure:

  • Access is gained via percutaneous umbilical cord blood sampling (cordocentesis) under ultrasound guidance.

  • A measured volume of fetal blood is aspirated to determine baseline hematocrit and remove circulating antibody-coated, hemolyzing red blood cells.

  • Fresh Group O-negative donor cells are infused into the umbilical vein.

  • Serial exchange transfusions are required at regular intervals because maternal $\text{IgG}$ antibodies persist in the fetal compartment, continuously targeting any newly generated native fetal red cells.

Questions and Discussion

• Inquiry Regarding Blood Selection for Intrauterine Transfusion:

  • Question: How is blood selected and administered for an intrauterine transfusion when the fetal ABO and Rh phenotype may not yet be established?

  • Response: Group O-negative ($O^-$) blood is routinely transfused. Because the fetal blood type is often unconfirmed at the onset of urgent therapy, Group O-negative blood guarantees immunological safety by preventing ABO- or Rh-mediated hemolysis by maternal antibodies.

• Inquiry Regarding Technical Execution of the Transfusion:

  • Question: What are the exact procedural steps involved during an intrauterine transfusion?

  • Response: Under ultrasound guidance, clinicians access the umbilical cord vein, extract a sample of fetal blood to remove heavily sensitized, hemolyzing erythrocytes, and slowly transfuse fresh donor red blood cells that lack the target antigen, effectively suppressing severe fetal anemia.

• Inquiry Regarding Maternal Benefit and Continued Transfusion Need:

  • Question: How does performing an intrauterine transfusion help a mother who has already developed circulating anti-D antibodies?

  • Response: The procedure provides no therapeutic benefit to the mother; her anti-D titers remain intact or may even rise. The procedure exclusively protects the fetus. Because maternal $\text{IgG}$ antibodies continuously cross the placenta and destroy native fetal red cells, repeat intrauterine transfusions or exchange transfusions are required throughout gestation until the fetus reaches a viable gestational age for delivery.

• Inquiry Regarding Diploid Gene Annotation in Practice:

  • Question: Because individuals possess two copies of every autosomal gene, why do some written clinical notations show only a single antigen listing, and how should genotypes be represented on examinations?

  • Response: Phenotype reports show only the expressed antigens detected by antisera (for example, showing positive for $C$ without clarifying whether the cell is $CC$ or $Cc$). When translating phenotypes to probable genotypes, both chromosomal homologues must be accounted for (for instance, writing $DCe/DCe$ or $DCe/dCe$). For examination evaluations, writing either homozygous $DD$ or heterozygous $Dd$ (using $d$ as a placeholder) is fully acceptable, though utilizing $d$ is a standard clinical precaution to allow for possible Rh-negative offspring.